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Abstract: High serum levels of the acute phase protein C-reactive protein (CRP) are associated with
an adverse prognosis in renal cancer. The acute phase reaction is cytokine-driven and includes a wide
range of inflammatory mediators. This overall profile of the response depends on the inducing event
and can also differ between patients. We investigated an extended acute phase cytokine profile for
97 renal cancer patients. Initial studies showed that the serum CRP levels had an expected prognostic
association together with tumor size, stage, nuclear grading, and Leibovich score. Interleukin (IL)6
family cytokines, IL1 subfamily mediators, and tumor necrosis factor (TNF)α can all be drivers of
the acute phase response. Initial studies suggested that serum IL33Rα (the soluble IL33 receptor
α chain) levels were also associated with prognosis, although the impact of IL33Rα is dependent
on the overall cytokine profile, including seven IL6 family members (IL6, IL6Rα, gp130, IL27, IL31,
CNTF, and OSM), two IL1 subfamily members (IL1RA and IL33Rα), and TNFα. We identified a
patient subset characterized by particularly high levels of IL6, IL33Rα, and TNFα alongside an
adverse prognosis. Thus, the acute phase cytokine reaction differs between renal cancer patients, and
differences in the acute phase cytokine profile are associated with prognosis.
Keywords: renal cell carcinoma; acute phase reaction; C-reactive protein; IL33Rα; IL1 family;
IL6 family; tumor necrosis factor α
1. Introduction
Renal cell carcinoma is a common malignancy and among the most lethal genitourinary cancers [1].
Standard treatment involves partial or radical nephrectomy for local tumors, whereas targeted therapies
can be considered for metastatic disease [2,3]. The systemic serum levels of several cytokines, especially
Interleukin (IL)6 are associated with prognosis in several urogenital cancers [4–6], including renal cell
carcinoma [7,8]. IL6 belongs to the IL6 cytokine family. These cytokines utilize glycoprotein 130 (gp130)
for intracellular signal transduction [9]. IL6 along with other family members are regulators of the acute
phase reaction and initiate intracellular signaling either through the cytokine binding to the complete
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membrane receptor (classical signaling) or through the binding of the soluble cytokine-receptor complex
to membrane-expressed gp130 (trans signaling) [9]. Thus, IL6 family cytokines form an interacting
network of soluble mediators, including the cytokines themselves together with their membrane-bound
and biologically active soluble receptor chains.
The acute phase reaction is a systemic response that accompanies acute and chronic inflammation.
It is triggered by tissue damage and characterized by the altered serum levels of several
inflammation-regulatory proteins, including C-reactive protein (CRP), and can be induced by IL6
family cytokines, as well as IL1β and tumor necrosis factor (TNF)α [10,11]. CRP binds a wide range of
exogenous and endogenous ligands; these complexes bind to Fc or CD14/Toll like receptors (TLRs),
thereby leading to a systemic plasma protein response involving several cytokines that reinforce the
initial CRP-inducing cytokine response [11]. IL6 is important for the release of several acute phase
proteins. The overall acute phase protein profile differs between various inducers, and other IL6 family
cytokines have effects similar to IL6 [10,12].
IL1 α/β are members of the IL1 subfamily of the IL1 cytokine family and are important in the
acute phase reaction together with the soluble IL1 receptor antagonist (RA) [13–16]. The release of
IL1RA by hepatocytes as part of the acute phase reaction is at least partly regulated by IL6 [17].
IL33 is another member of the IL1 subfamily of cytokines, and the soluble IL33 receptor α chain
(IL33Rα) should also be regarded as an acute phase protein [18–21]. IL33 binds to IL33Rα, which forms
a dimer with the signal-initiating IL1RAcP co-receptor [22]. The same co-receptor is utilized by the
IL1 receptor chain [22]. The soluble IL33 receptor IL33Rα (sIL33Rα) is a decoy receptor that shows
altered systemic levels in several diseases [23,24] and is identical to the extracellular region of the
membrane-bound (referred to as IL33Rα long or IL33RαL) chain, except for five additional amino
acids [25–28]. A third IL33RαV variant, with another hydrophobic tail and lacking one extracellular
domain, also exists [29]. IL33RαL is expressed by various cells, including epithelial, endothelial,
and immunocompetent cells [25,30]; IL33RαV is expressed by certain epithelial and immune cells [25];
sIL33Rα is released by several cells, including kidney and immunocompetent cells [25]; and IL33 is
expressed mainly by non-hematopoietic cells [30]. Downstream receptor signaling involves MyD88
and several of its downstream pathways that ultimately target NF-κβ and AP-1 [30], but IL33 can also
bind to chromatin or directly inactivate NF-κβ [30–33]. Its final effect seems to be the stimulation of
renal carcinogenesis [27].
Tumor diameter [34] and preoperative serum CRP levels are independent prognostic parameters
in non-metastatic renal cell carcinoma; CRP thus serves as a marker of the acute phase reaction [35].
The aim of the present study was to characterize the heterogeneity of the cytokine-driven acute phase
reaction (i.e., the biological context of CRP) in patients with renal cell carcinoma by investigating
an extended pre-therapy acute phase cytokine profile that includes seven IL6 family members,
IL1 subfamily members (IL33Rα and IL1β/IL1RA), and TNFα.
2. Results
2.1. Clinical, Biological, and Prognostic Characteristics of the Renal Cancer Patients
During a defined time period, 154 patients were surgically treated for renal cancer. They all
gave their written informed consent but due to practical or technical reasons, a preoperative serum
sample could be collected only for 118 patients. These 118 patients included 9 with metastatic and
109 with local disease. Our hospital is responsible for the treatment of all renal cancer patients for a
defined geographical area, and our patient cohort represents all diagnosed patients from a defined time
period. The characteristics of the whole patient cohort and for the patients only with non-metastatic
disease are presented in Table 1, whereas the characteristics of the patients who could not be sampled
preoperatively due to practical or technical reasons are given in Table S1.
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Table 1. Clinical and tumor characteristics of patients with renal cell carcinoma scheduled for surgery
during the period 2007–2010; the table presents the results for all 118 patients for whom a preoperative
serum sample was available (unless otherwise specified) and for the patients with local renal cancer
disease (i.e., without metastases). The results are presented as the median and interquartile (if specified)
range for continuous variables, except for long-term survival. Categorical data are expressed as
numbers with a percentage (or in specified cases interquartile range) in parenthesis.
Parameter All Patients(n = 118)
Patients without Metastases
(n = 109)
Age in years at diagnosis (interquartile range) 63.8 (55.1–2.5) 63.9 (55.4–73.5)
Gender; male/female 88 (74.6)/30 (25.4) 80 (73.4)/29 (26.6)
Charlson Comorbidity Index (interquartile range) 1 (0–2) 1 (0–2)
ASA score (interquartile range) 2 (2–2) 2 (2–2)
Surgical treatment
Radical nephrectomy 80 (67.8) 71 (65.1)
Partial nephrectomy 38 (32.2) 38 (34.9)
Peripheral blood levels
B-Hemoglobin (g/dL, n = 100/91) 14.2 (8.8–17.3) 14.0 (8.8–17.3)
Erythrocyte sedimentation rate (mm, n = 92/84) 13 (2–129) 14 (2–129)
S-creatinine (µM, n = 100/91) 76.5 (45–725) 77.0 (45–725)
S-calcium (mM, n = 99/90) 2.40 (1.96–3.00) 2.40 (1.96–3.00)
S-alkaline phosphatase (U/L, n = 96/87) 81 (45–527) 81 (45–527)
S-CRP (mg/L, n = 116/107) 3 (1–220) 3 (1–112)
Tumor size (cm) 1 5.3 (1.9–17.5) 4.9 (1.9–16.8)
≤7.0 76 (64.4) 74 (67.9)
>7.0 42 (35.6) 35 (32.1)
Histology
Subtype
Clear cell 91 (77.1) 83 (76.1)
Papillary 14 (11.9) 14 (12.8)
Chromophobe 6 (5.1) 6 (5.5)
Multilocular cystic 5 (4.2) 5 (4.6)
Others/unclassified 2 (1.7) 1 (0.9)
Nuclear grade
G1-G2 62 (52.5) 62 (56.9)
G3-G4 55 (46.6) 46 (42.2)
Unknown 1 (0.9) 1 (0.8)
Detectable metastases at the time of diagnosis 2 9 (7.6) Not relevant
Observation time (months) 3 100 (4–120) 103 (11–120)
Long-term overall survival (mean, standard error) 4 96.5 (3.5) 101.7 (3.3)
Long-term recurrence-free survival (mean, standard error) 4 106.0 (3.0) 112.3 (2.3)
1 Tumor size was measured on CT scans. The complete tumor-node-metastasis (TNM) staging of the patients
included in the present cytokine study is given in Table S2 [36,37]. All patients with metastases had tumor diameters
> 4 cm. 2 Clinical examination together with CT scans of the abdomen and chest were used to classify patients as
with or without metastases. 3 Patients were observed from the time of diagnosis until death or until November 2018.
4 Median survival was not reached.
The whole patient cohort included nine patients with detectable metastatic disease at the time of
diagnosis. The 109 patients with non-metastatic disease included 80 surviving patients, 11 patients
who died from relapsed cancer, and 18 patients who died from other causes. The IL33Rα levels
were determined for 96 patients and the other nine cytokines for 97 patients (one additional patient);
six patients with metastatic disease were included for all the mediators. These 97 patients comprise
of all patients who were sampled during the study period without additional selection. Our cohort
included 70 survivors, six patients who died from their metastatic cancer disease detected at the time
of diagnosis, 7 additional patients who also died from their renal cell carcinoma, and 14 patients who
died from other causes.
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We compared the clinical and biological parameters listed in Table 1 for potentially cured patients
(i.e., no detectable metastases at the time of diagnosis) with those of cancer-free survivors and patients
who later died from relapse/metastases. These last two groups differed significantly from the cancer-free
survivors with regard to their serum CRP levels (p = 0.003), frequency of large tumors at the time
of diagnosis (p < 0.001), and frequency of Fuhrman G3-G4 nuclear grading (p = 0.001). All these
parameters are regarded as prognostic factors for renal cancer patients, and these differences are,
therefore, expected [38–42]. Thus, these patient characteristics show that our cohort of renal cancer
patients can be regarded as representative. The patients included in our cytokine studies were randomly
selected from the 118 patients in the cohort.
2.2. The CRP Levels in Renal Cancer Patients; Strongest Associations with Tumor Characteristics, Weak
Associations with Comorbidity, and Only Associated with IL6 among the Ten Cytokine Mediators
The acute phase reaction can be initiated by inflammation and tissue damage, but epidemiological
studies have also demonstrated that the CRP levels in elderly individuals can be associated with
frailty or comorbidity, i.e., they can be a part of the aging process [43–46]. We thus investigated
whether the CRP level at the time of diagnosis was significantly associated with clinical characteristics,
tumor characteristics, comorbidity scores, or cytokine serum levels (Table S3). The preoperative CRP
levels showed the strongest associations with tumor stage (i.e., diameter; Kendall’s τ 0.315) and the
presence of necrosis in the tumor (Kendall’s τ 0.332). The Eastern Cooperative Oncology Group
(ECOG) performance status showed an association of borderline significance, whereas the Charlson
comorbidity index and the American Society of Anesthesiologists (ASA) physical classification score
showed no associations. Thus, the CRP level mainly reflected the characteristics of the malignant
disease among the patients.
Preoperative serum CRP levels showed a correlation with IL6 levels (Kendall’s τ 0.301, p < 0.001),
whereas no significant correlation with CRP was seen for the IL1 subfamily mediators IL33Rα (Kendall’s
τ 0.173) or IL1RA (Kendall’s τ 0.246). For the other IL6 family members and TNFα, the Kendall’s τ
value was generally lower (usually < 0.10) and/or associated with p-values > 0.10. IL6 is regarded as a
major driver of the acute phase reaction [10], and an association between the CRP and IL6 levels is,
therefore, not unexpected. The systemic IL1β levels were generally low with minor variations and
undetectable levels in several patients; the detection of low IL1β levels is consistent with previous
studies of cancer patients [47]. Thus, high IL6 levels are an additional phenotypic characteristic of the
acute phase reaction for renal cancer patients with high CRP levels, whereas variation in the other
acute phase cytokine mediators is not reflected by CRP in renal cancer patients.
2.3. Serum Levels of the IL1 Subfamily Mediators IL33Rα and IL1RA Show No Significant Correlation; Only
IL33Rα Is Increased in Metastatic Disease, and Only IL33Rα is Associated with Survival
The preoperative serum levels of IL33Rα and IL1RA did not show any significant correlation.
We also classified the patient subset with non-metastatic disease into three groups based on their
IL33Rα/IL1RA levels: (i) both with levels above the corresponding median; (ii) only one of the
mediators having a level above the median; and (iii) both levels below the corresponding median.
These three patient subsets did not differ in their overall survival. Finally, neither the IL33Rα nor
IL1RA serum levels showed any significant associations with ECOG performance status, ASA score,
Charlson comorbidity index, tumor size, or Fuhrman nuclear grading.
The IL33Rα levels were significantly higher for patients with metastases (n = 6, median level
29,130 pg/mL, range 23,520–162,569 pg/mL) compared to the patients with non-metastatic disease
(n = 90, median 22,656 pg/mL, range 7053–75,572 pg/mL, Wilcoxon’s rank sum test, p = 0.017). We also
classified our patients with non-metastatic disease based on their tumor stage. The IL33Rα levels for
patients with large tumors (i.e., diameters > 7 cm) differed significantly from patients with metastatic
disease (p = 0.038) but not from the patients with non-metastatic disease and small tumors (Figure 1).
In contrast, the IL1RA levels for patients with metastatic disease (n = 6, median 802 pg/mL, range
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335–1607 pg/mL) did not differ significantly from those of patients without metastases (n = 91, median
684 pg/mL, range 281–2711 pg/mL), and IL1RA also did not differ between patients with non-metastatic
disease and those with metastatic disease or between those with small versus large tumors without
metastases. Thus, IL33Rα and IL1RA belong to the same IL1 cytokine subfamily and should both
be regarded as acute phase mediators. Nevertheless, these two mediators differ in metastatic versus
non-metastatic disease and thereby contribute to the heterogeneity of the acute phase cytokine reaction
in renal cancer patients.
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Figure 1. Preoperative IL33Rα serum levels in patients with renal cell carcinoma; a comparison of
patients with small tumors (≤7 cm in diameter) with no metastases, with large tumors (>7 c ) and no
metastases, and etastatic disease.
We thus investigated the association between survival and the IL33Rα level, CRP level, Leibovich
score, tumor size, Fuhrman’s nuclear grading, ASA score, and age via univariate Cox prediction
analyses. We then examined the death from renal cancer and overall survival for the patients who
were classified as radically treated after surgery (Table 2). IL33Rα showed an association of borderline
significance with cancer-related death, whereas highly significant associations were observed for the
tumor characteristics and CRP levels. For overall survival, significant associations were seen for
the tumor characteristics, serum CRP, and patient age, whereas IL33Rα did not reach significance.
Finally, IL1RA showed no significant associations with cancer-related death or overall survival in the
Kaplan–Meier or Cox analyses.
The Leibovich score is used for the prognostic evaluation of patients with renal cancer [38,40,42,48].
We, therefore, investigated the IL33Rα levels and Leibovich score using a multivariate analysis for
patients with a clear-cell subtype of kidney malignancy. We had relatively few cancer-related deaths
in our cohort, and for this reason, we included only these two parameters. Moreover, the Leibovich
score was chosen because it includes several prognostic parameters, and the IL33Rα level remained
significant when corrected for the Leibovich score (Table 3).
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Table 2. Univariate Cox survival predictions in radically treated renal cell carcinoma patients using
serum IL33Rα and CRP, as well as the included clinico-histopathological parameters. Values are given
as the hazard ratio (95% confidence interval). The whole patient cohort included 109 patients, but the
IL33Rα levels were analyzed for 90 randomly selected patients. Other values that differ from n = 109
are specified.
Variable Disease-Specific Survival Overall Survival
IL33Rα (ng/mL), n = 90 1.05 (1.00–1.09) p = 0.034 1.02 (0.99–1.06) p = 0.178
CRP (mg/L), n = 107 1.03 (1.01–1.04) p = 0.011 1.02 (1.01–1.04) p < 0.001
Age 1.05 (0.99–1.11) p = 0.083 1.07 (1.03–1.11) p = 0.001
ASA score 1.43 (0.49–4.19) p = 0.510 1.38 (0.71–2.68) p = 0.342
Tumor size 3.40 (1.58–7.31) p = 0.002 1.66 (1.15–2.39) p = 0.006
Pathological TNM stage 4.53 (2.44–8.44) p < 0.001 2.13 (1.43–3.18) p < 0.001
Fuhrman nuclear grading, n = 108 2.51 (1.26–4.98) p = 0.009 1.61 (1.22–2.11) p = 0.001
Leibovich score, n = 82 * 4.03 (1.81–8.97) p = 0.001 1.91 (1.19–3.08) p = 0.007
* Patients with clear-cell renal cancer; value missing for one patient.
Table 3. The impact of IL33Rα for progression in 67 patients randomly selected out of 83 patients
with clear-cell renal cell carcinoma assumed to be radically treated; a multivariate analysis including
IL33Rα together with the Leibovich score. The results are presented as the hazard ratio (95% confidence
interval) and p-values.
Variable Progression-Free Survival
IL33Rα (ng/mL) 1.07 (1.01–1.14) p = 0.020
Leibovich, intermediate risk (score 3–5) * 26.9 (2.1–352.0) p = 0.012
Leibovich, high risk (score ≥ 6) * 49.5 (4.3–576.0) p = 0.002
Leibovich, overall - p = 0.008
* Compared to patients in the low-risk Leibovich group (score ≤ 2), with the maximum score being 11 [38].
2.4. The IL6 Cytokine Family Profile Identifies Patient Subsets That Differ in the Prognostic Impact of IL33Rα,
Whereas the Impact of IL1RA/TNFα Does Not Differ
We investigated the serum levels of the IL6 family cytokines IL6, IL27, IL31, CNTF, and OSM,
together with the soluble receptor components gp130 and IL6Rα. These IL6 family mediators
form an interaction network through their overlapping receptor binding (with gp130 as a common
signal-initiating receptor chain), common downstream intracellular signaling, and the potential for both
classical and trans signaling (i.e., binding of the soluble receptor/ligand complex to membrane-expressed
gp130) for several of these cytokines [9]. The overall results were investigated by hierarchical clustering
analysis (Figure 2). CNTF and IL6 had the widest variation ranges among the included mediators.
This analysis identified two main patient subsets that did not differ with regard to the serum levels
of the IL6 family mediators, IL1 subfamily mediators, TNFα, or CRP. Finally, the number of patients
dying from renal cancer (i.e., patients with metastases at diagnosis or later relapse) or dying from other
causes did not differ between the two main patient clusters.
Each of these two main clusters was further divided into two subclusters characterized mainly by
differences in their IL6 and CNTF levels, as indicated to the right in Figure 2. Patients included in
the two sub-clusters are characterized by low or relatively low levels of IL6 and/or CNTF (Figure 2
right part, indicated by the blue color in the figure and referred to as IL6lowCNTFlow patients). We first
compared the soluble mediator levels for the IL6highCNTFhigh and IL6lowCNTFlow patients (Table S4).
The systemic IL1RA levels were significantly higher for the IL6lowCNTFlow patients (median 736 pg/mL,
range 371–2710, Wilcoxon’s test, p = 0.027) compared to the IL6highCNTFhigh patients (656 pg/mL,
range 280–1493). The systemic levels of CRP, TNFα, and other IL1 subfamily or IL6 family mediators
did not differ significantly between these two patient subsets. Lastly, the number of patients dying
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from renal cancer (i.e., patients with metastases at diagnosis or later relapses) or dying from other
causes also did not differ between the IL6highCNTFhigh and IL6lowCNTFlow patients.
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We used Kaplan–Meier analyses to compare the associations between IL33Rα levels and
cancer-related death (metastases or relapse) for the IL6lowCNTFlow and IL6highCNTFhigh patients
(see Figure 2). Patients were classified into quartiles based on the IL33Rα variation range. Patients
in the three lower quartiles showed a similarly low mortality for both the IL6lowCNTFlow and
IL6highCNTFhigh subsets and were, therefore, classified together and compared with the patients in the
highest quartile. The results are presented in Figure 3. A significant association between prognosis
and IL33Rα levels was only observed for the IL6lowCNTFlow patients, whereas such an association
was not detected for the IL6highCNTFhigh patient subset. Thus, the prognostic impact of a single acute
phase mediator (i.e., IL33Rα) may differ between patient subsets identified by the acute phase cytokine
profile (i.e., the IL6 family profile). This prognostic impact only for certain patients may also explain
why IL33Rα levels did not differ when comparing the survivors and non-survivors in our whole study
population (Figure S1).
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Figure 3. Comparison of kidney cancer-related death for the patient subsets identified in the hierarchical
clustering analysis based on IL6 family mediators. As indicated in Figure 2, the 97 patients could be
sub-classified into the two main subsets referred to as (left) IL6highCNTFhigh and (right) IL6lowCNTFlow
subsets. The patients were classified into quartiles based on their IL33Rα serum levels, and we
compared the survival of patients classified in the highest versus the three lowest IL33Rα quartiles.
The IL6highCNTFhigh (left) and IL6lowCNTlow patients (right) were analyzed separately. The p-values
are indicated in the figure images.
2.5. The Prognostic Impact of an Extended Acute Phase Cytokine Profile for Renal Cancer Patients
Our IL6 family cytokine profiling (Figure 2) clearly illustrates that the acute phase reaction in
patients with renal cell carcinoma possessed heterogeneity that was only partly reflected in the CRP
level. To further investigate the prognostic impacts of these differences on the acute phase profile,
we performed a hierarchical clustering analysis based on TNFα, two IL1 subfamily mediators (IL1β was
not used due to undetectable levels in many patients and only minor variations between patients),
and the seven IL6 family members. Our present and previous studies suggest that IL33Rα is associated
with the acute phase reaction. Moreover, previous studies have shown that the nine other mediators
are involved in the regulation of the acute phase response (see Section 1). The results of this clustering
analysis are shown in Figure 4. After this analysis, two main patient subsets were identifiable.
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We performed a Kaplan–Meier survival analysis comparing the two main subsets identified in
Figure 4. This analysis is presented in Figure 5. As shown, the two patient clusters differed in their
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disease-specific survival. As expected from the results presented in Figure 4, the two main patient
clusters did not differ in their overall survival, indicating that most of the patients (14 patients) died
from other cases, and only 13 patients (six with metastases at the time of diagnosis) died from their
malignant disease.
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hierarchical clustering analysis based on the systemic levels of 10 cytokine mediators (see Figure 4; upper
main cluster 1, lower main clust 2). Al 97 patients were i clud d in this comparison. A Kaplan–Meier
analysis was performed, and the p-value for this comparison is indicated in the figure.
We ultimately compared the serum levels of all acute phase proteins, including the CRP levels,
between the two main subsets identified (Table 4). The two subsets showed highly significant differences
in their IL6, IL33Rα, and TNFα evels, whereas their IL1RA and CRP levels showed differences of only
borderline significance. The IL6 and IL33Rα differences remained significant even after Bonferroni
corrections. Thus, the two main patient clusters were mainly determined by the levels of the three
mediators, and this sub-classification, therefore, was determined by acute phase characteristics that are
only partly reflected in the serum CRP levels.
Table 4. The serum mediator levels in patients with renal cancer; a comparison of the two main patient
subsets identified in the unsupervised hierarchical cluster analysis based on the seven IL6 family
members (gp130, IL6Rα, IL6, IL27, IL31, OSM, and CNTF), two IL1 subfamily members (IL1RA and
IL33Rα), and TNFα. The results are presented as the median level and variation range. The table
presents the levels of the IL6 family members included in the clustering analysis together with the
levels of IL1RA, IL33Rα, TNFα, and CRP.
Mediator (Concentration) Upper Main Cluster(n = 73)
Lower Main Cluster
(n = 24) p-Value
gp130 (pg/mL) 92,745 (22,606–121,962) 88,475 (24,351–108,820) 0.332
IL6 Rα (pg/mL) 34,382 (17,789–48,588) 34,057 (22,510–46,610) 0.536
IL6 (pg/mL) 2.9 (0.0–16.3) ↑ 12.1 (0.5–73.2) <0.001
IL27 (pg/mL) 673 (254–1173) 795 (367–2738) 0.188
IL31 (pg/mL) 196 (87–584) 160 (83–410) 0.058
OSM (pg/mL) 5789 (4500–7911) 5636 (3827–7003) 0.347
CNTF (pg/mL) 454 (98–2555) 274 (98–1961) 0.548
IL33Rα (pg/mL), n = 72/24 21,842 (7053–75,572) ↑ 26,652 (15,853–162,569) 0.001
IL1RA (pg/mL) 670 (281–2237) ↑ 876 (488–2711) 0.044
TNFα (pg/mL) 24.5 (6.8–37.2) ↑ 27.8 (18.1–37.9) 0.006
CRP (mg/L), n = 71/24 3 (1–19) ↑ 5 (1–220) 0.021
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3. Discussion
The serum CRP level is a generally accepted prognostic factor for patients with renal cell
carcinoma [41,49]. However, CRP is only one of several acute phase proteins, and the systemic serum
profiles of acute phase cytokines (i.e., potential drivers of the acute phase reaction) seem to differ
between patients and may also depend on the cause of the acute phase reaction [10]. In this context
we investigated the acute phase cytokine profiles among a large group of patients with renal cancer
admitted for surgical treatment.
As described above, our original cohort of 118 patients (109 without metastases) represents an
unselected group of patients, i.e., the patients were derived from a defined geographical area during a
defined time period and included all patients that could be sampled before surgery. The 97 patients
included in our present study were randomly selected from this cohort. For this reason, we regarded
our patients to be representative. Only a minority of the patients had advanced disease, while a
majority of the patients had stage T1 tumors and tumor-node-metastasis (TNM) stage I (see Table S2).
As expected, the cancer-free survival was high, but due to the high median age, several patients died
from causes other than their cancer.
We cannot exclude the possibility that inflammaging (i.e., inflammation associated with aging,
see [50]) or other chronic inflammatory diseases contributed to the observed acute phase reaction.
However, we did not perform any additional selection of patients included in our present cytokine
studies. Our present results should, therefore, be regarded as real-word data from a representative
group of patients with renal cancer. We cannot exclude the possibility that the acute phase reaction
in some of our patients may have been, at least partly, caused by inflammaging or nonmalignant
chronic inflammatory diseases, but, despite this, we still detected a prognostic impact of the acute
phase cytokine response when investigating our unselected patients. None of the survival analyses
demonstrated different results with the inclusion of age, Charlson comorbidity index, ASA score,
and ECOG performance status as co-variates.
Recent studies show that CRP is an important regulator in inflammation, but in clinical practice,
it is used as a marker of both inflammation and the complex acute phase reaction [11]. The aim of the
present study was to investigate the biological context of CRP (i.e., the acute cytokine network response
and the acute phase reaction) in a representative cohort of patients with renal cancer. Our selection
of mediators was based on previous studies showing that IL1, TNFα, and IL6 are important in
the development of the acute phase reaction [10]. First, the IL1 cytokine family includes the IL1
subfamily [22] with the members IL1α/β and IL33, their receptors, and the antagonistic IL1RA. The IL1
and IL33 binding receptor chains co-localize with the same signal-initiating IL1RAcP co-receptor [22].
We, therefore, included IL1β together with its antagonist IL1RA in our present study [10,11,22].
In addition, we included the soluble IL33 decoy receptor IL33Rα because this biomarker should also
be regarded as an acute phase protein (i.e., a systemic marker of inflammation) [18–21], but we did
not include IL33 itself because it is produced by renal cancer cells and its local release is likely more
important [51]. Second, we included TNFα, which is an acute phase cytokine and also important for
the development of the acute phase reaction [10]. Finally, we investigated the levels of IL6 family
members and soluble IL6 receptor components because IL6 is an important regulator of the acute phase
reaction [10], and the systemic IL6 level also seems to have a prognostic impact on renal cancer [52–54].
We focused on the IL6 cytokine family profile because several such family members contribute to
the regulation of the acute phase response. Their receptor binding partly overlaps, their intracellular
signaling is similar, and several of them show both classical and trans signaling [9,10]. We then
included IL6 family members that show systemic levels in a majority of immunocompetent and
immunocompromised individuals [55,56].
We investigated a relatively large group of renal cancer patients that were randomly selected from
a consecutive group of patients. Our patients should be regarded as representative in their clinical
(e.g., age, performance status, and survival), biological (e.g., tumor and cancer cell characteristics),
and prognostic parameters (e.g., Leibovich score, tumor characteristics, and CRP level). However, our
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patients had a long follow-up time. For this reason, Fuhrman nuclear grading was used at the time of
inclusion instead of the newly recommended system [41,57].
The prognostic impact of CRP shows that the acute phase reaction is important in renal
cell carcinoma [39,58–60]. CRP is not only a marker but also a mediator with distinct biological
functions [61–63]. However, the systemic acute phase reaction is a very complex response, and the
aim of our present study was, therefore, to investigate the systemic levels of acute phase cytokines
in renal cancer patients with a focus on the acute phase cytokine profiles, rather than those of single
cytokines. IL6 family cytokines were included because they are important regulators of the acute
phase reaction [10], but we investigated only IL6 family cytokines that usually show detectable serum
levels [55,56]. IL1β/IL1RA and TNFα are important in the regulation of the acute phase response [10].
The inclusion of IL33Rα in our acute phase cytokine profile is justified by our present results, describing
an association between IL33Rα levels and prognosis, and by those of previous studies showing that
IL33Rα is an acute phase protein [18–21].
Studies on several malignancies (including renal cancer) suggest that the IL33/IL33Rα axis could
be important in tumorigenesis through exerting direct effects on malignant cells [64] or indirectly
through effects on stromal cells [65], including altering the regulation of tumor angiogenesis [66].
An association between serum IL33Rα levels and prognosis has been described for patients with
hepatocellular carcinoma [67] and breast cancer [68]. A recent study also investigated serum IL33 levels
and tumor IL33 expression via immunocytochemistry for renal cancer patients [27]. A high tumor
expression of IL33 was then associated with advanced disease and an adverse prognosis; additional
experimental studies showed that IL33 enhanced cancer cell growth and induced chemoresistance.
A similar prognostic impact was described in another retrospective study that also assessed IL33
tumor expression via immunohistochemical staining [51]. However, yet another study described
an adverse prognostic impact from the low renal cancer expression of IL33 at the mRNA level [26].
The use of different methodological approaches may explain this discrepancy. We also observed a
possible prognostic impact of sIL33Rα independent of the Leibovich score, which is mainly based
on tumor characteristics [38], but the low number of cancer-related deaths represents a limitation
for the statistical analysis of patient survival in our present study. Finally, the immunoregulatory
functions of IL33/IL33Rα may also be important for the effect of this axis on human malignancies,
e.g., through induction of Treg cells or the inhibition of antigen presentation [26,33,69,70]. For these
reasons and because of the similarities in downstream receptor signaling between IL1 and IL33, we
included sIL33Rα in our acute phase cytokine profile together with IL1β and IL1RA. This was further
supported by previous studies showing that IL33Rα is associated with prognosis in renal cancer and
represents a systemic marker of inflammation [71].
We investigated IL6 family members that have detectable serum levels in most healthy
individuals [55,56]. IL6 family cytokines have similarities in their receptor structures, with gp130
being the common signaling structure for all the receptors; in addition, some of the receptors can bind
different IL6 family cytokines, and several family members are capable of both classical and trans
signaling. For this reason, one should regard this family as the IL6 family network. We, therefore,
focused on the IL6 family profile rather than on single family members. Even though several of these
members seem to be involved in regulating the acute phase response, differences in the IL6 family
profile could be used to identify patient subsets by hierarchical clustering analyses. However, the main
subsets identified by hierarchical clustering based on IL6 family cytokines showed no association with
CRP levels or patient survival (Figure 2). Finally, even though IL6 and CRP levels showed a significant
correlation, the levels of these two cytokines did not differ when comparing the two main patient
subsets (i.e., IL6highCNTFhigh versus IL6lowCNTFlow patients, see Figure 2). This is likely due to the
impact of other IL6 family members (especially CNTF) in this IL6 family-based cluster analysis. This is
also consistent with our observation that IL6 is the only cytokine biomarker presenting a significant
correlation with CRP levels.
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We ultimately performed a hierarchical clustering analysis based on TNFα, two IL1 subfamily
members, and seven IL6 family members. Based on this overall acute phase cytokine profile,
we identified two main subsets. These two subsets were not independent of the CRP level but differed
significantly with regard to patient survival. The majority of patients dying from their malignant
disease (metastatic disease at the time of diagnosis, later death from relapse) were included in a cluster
characterized by especially higher levels of IL6, IL33Rα, and TNFα compared to the other main cluster,
whereas IL1RA and CRP only showed differences with borderline significance. The IL6 and IL33Rα
differences remained significant even after Bonferroni corrections. Thus, the overall clustering analysis
based on an acute phase profile identified two main subsets. The patient survival differed between
these two subsets, and this prognostic impact mainly reflected differences in IL6/IL33Rα/TNFα.
4. Materials and Methods
4.1. Patients
This retrospective biobank study was approved by the regional ethics committee (REK VEST
78/05) and the Norwegian Social Science Data Services; the study was conducted in accordance
with the Declaration of Helsinki. Blood samples were collected after written informed consent from
118 consecutive patients with newly diagnosed renal cell carcinoma during the time period of 2007–2010
(median observation time 100 months, range 4–120 months). All patients were followed according
to our risk-stratified follow-up program for surgically treated renal cell carcinoma [72]. The present
study included 97 randomly selected patients from this cohort. The patient and tumor characteristics
are presented in Table 1 and Table S2.
4.2. Analyses of CRP Levels
CRP levels were analyzed using the immunoturbidimetric method provided by Roche
(Basel, Switzerland). During the entire period, the lower limit of detection for the serum CRP
was 1 mg/L.
4.3. Blood Sampling and Cytokine Analyses
Peripheral venous blood samples were collected on the morning of the day of the planned renal
cancer surgery. Samples were stored at room temperature for less than two hours before they were
centrifuged. The serum was collected, aliquoted, and later stored frozen at −80 ◦C until being analyzed.
Samples derived from the 97 unselected patients were available for analyses. The samples were
then thawed and centrifuged at 16,000× g for 4 min immediately before analysis. The IL6 levels
were analyzed by a high-sensitivity ELISA kit (R&D Systems Europe Ltd., Abingdon, UK). Gp130,
IL6Rα, IL27, IL31, OSM, IL1RA, and TNFα were determined using a Human Premixed Multi-Analyte
Kit for Luminex technology (R&D Systems). IL33Rα was also determined using Luminex analyses
(R&D Systems). A Human Pituitary Magnetic Bead Panel 1 was used to measure CNTF (EMD Millipore
Corporation, Billerica, MA, USA). All analyses were performed strictly according to the manufacturer’s
instructions and the levels estimated by using a Luminex® 100TM (Luminex Corporation, Austin, TX,
USA). All results are presented as the mean level of duplicate determinations.
One patient sample was included in all assays to evaluate the inter-platelet variation, but we did
not detect any substantial differences between assays. The variation between duplicates was generally
less than 10% of the mean concentration. Neither IL33Rα nor IL1RA levels showed any correlations
with the sample storage time.
4.4. Statistical and Bioinformatical Analyses
The IBM® SPSS® Statistics software, version 25.0 (IBM Corp., Armonk, NY, USA), was utilized.
A comparison of descriptive data was performed using cross-tables and an exact Chi-square test.
A Mann–Whitney U test was used for a comparison between different groups, and Kendall’s tau (τ)
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was used for correlation analyses. Kaplan–Meier analyses were used for the percentage estimation of
outcome prediction, including a Log-Rank test between groups. Cox proportional hazard models were
also used for survival analyses. A p-value < 0.05 was regarded as statistically significant. Correction
for multiple comparisons was done by Bonferroni. Bioinformatical analyses were performed using
J-Express (MolMine AS, Bergen, Norway) [73]. All cytokine and receptor levels were normalized by
their median values, naturally log-transformed, entered into a complete linkage, and used to generate
hierarchical clustering. The distance measures were Euclidean.
5. Conclusions
The systemic levels of the acute phase protein CRP are a generally accepted prognostic factor for
renal cell carcinoma. Our present study shows that the acute phase cytokine profile differs between
renal cancer patients, and most cytokine serum markers included in our present study showed no
association with serum CRP levels. Based on differences in the overall acute phase cytokine profile,
we classified renal cancer patients into two main subsets that differed significantly with regard to
prognosis. Our results suggest that the possible prognostic impact of an extended acute phase cytokine
profile or acute phase proteins other than CRP depends on biological context and differs between
patient subsets. The possible prognostic impact of the acute phase cytokine profiles should be further
investigated for patients with renal cell carcinoma. However, the cancer-related patient death was
relatively low in our patient cohort, and the possible prognostic impact of these phenotypic differences
in the acute phase reaction has to be further investigated in larger patient cohorts.
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Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral
accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 2013, 134, 1669–1682.
[CrossRef]
71. Stankovic, M.S.; Janjetovic, K.; Velimirovic, M.; Milenković, M.; Stojković, T.; Puskas, N.; Zaletel, I.;
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